AI-Sight
AI Sight Limited is a UK-based company that commercializes a next-generation AI system for diabetic retinal screening. Their flagship product, AI-Sight, is a highly sensitive, specific, and low-cost web-based diagnostic tool designed to provide WHO-recommended diabetic eye screening services globally. The system interprets images across diabetic retinopathy disease severity and treatment intervention points, uniquely offering an indication of certainty in its grading by identifying borderline and contentious cases for human assessment. This feature addresses adoption hesitancy and differentiates AI-Sight from other AI diagnostic tools, which are often cumbersome, time-consuming, and require expensive retraining. The company is led by a team of world-leading researchers, clinicians, and healthcare experts, and has spun out from the University of Liverpool. AI Sight targets markets with significant unmet needs, including over 180 countries lacking diabetic retinopathy screening programs, aiming to reduce the leading cause of working-age blindness worldwide.
AI-Sight
AI Sight Limited is a UK-based company that commercializes a next-generation AI system for diabetic retinal screening. Their flagship product, AI-Sight, is a highly sensitive, specific, and low-cost web-based diagnostic tool designed to provide WHO-recommended diabetic eye screening services globally. The system interprets images across diabetic retinopathy disease severity and treatment intervention points, uniquely offering an indication of certainty in its grading by identifying borderline and contentious cases for human assessment. This feature addresses adoption hesitancy and differentiates AI-Sight from other AI diagnostic tools, which are often cumbersome, time-consuming, and require expensive retraining. The company is led by a team of world-leading researchers, clinicians, and healthcare experts, and has spun out from the University of Liverpool. AI Sight targets markets with significant unmet needs, including over 180 countries lacking diabetic retinopathy screening programs, aiming to reduce the leading cause of working-age blindness worldwide.